header advert
Orthopaedic Proceedings Logo

Receive monthly Table of Contents alerts from Orthopaedic Proceedings

Comprehensive article alerts can be set up and managed through your account settings

View my account settings

Visit Orthopaedic Proceedings at:

Loading...

Loading...

Full Access

O2631 HYBRID ALUMINA TOTAL HIP ARTHROPLASTY IN PATIENTS YOUNGER THAN 55 YEARS. A 6- TO 11-YEAR EVALUATION



Abstract

Aim: The aim of the study was to analyze the results of hybrid alumina prothesis using a pressþt metal backed socket and a cemented stem in young and active patients. Methods: From 1990 to 1992, 71 hybrid alumina-onalumina hip replacements were performed in 62 consecutive patients under age 55, with a mean age of 46 years at surgery. There were 56 primary procedures and 15 revision procedures. The prostheses included a cemented Ti alloy stem, a 32-mm alumina head, and a press-þt metal backed socket with an alumina insert. Results: 3 patients (4 hips) died from unrelated causes. 4 hips had revision surgery for deep infection, unexplained persistant pain, fracture of alumina head, and socket aseptic loosening. The 9-year survival rate was 93.7% if revision for any cause was the end point, and 98.4% if revision for aseptic loosening was the end point. Results in surviving patients with a minimal 5-year followup and an average followup of 8 years (57 hips) were excellent in 47 hips (82.5%), very good in 8 hips (14%), good in 1 hip and fair in one hip. 38% of the sockets had a thin and partial lucent line and 1 socket had a complete lucency less than 1mm thick. One stem had isolated femoral osteolysis. There was no detectable component migration nor acetabular osteolysis. Conclusion: Hybrid alumina prosthesis gave satisfactory results at mid term in active patients. Press-þt metal backed socket appeared as a reliable method of acetabular þxation in alumina-alumina hip replacement. Excellent results of cemented stem þxation may be related to low wear debris production.

Theses abstracts were prepared by Professor Dr. Frantz Langlais. Correspondence should be addressed to him at EFORT Central Office, Freihofstrasse 22, CH-8700 Küsnacht, Switzerland.